This will give information about CEO of Seattle Genetics, Dr. Clay Siegall. An article will be recapped by “Ideamensch”, a type of “In Health, Interviews” article called “Clay B. Siegall-Co-Founder of Seattle Genetics”. Then, general information about him and his professional life will be given later. With the leadership of the Doctor ”Seattle Genetics” has walked into different strategic licenses for technology under ADC. For example he has done it with “AbbVie” and GlaxoSmithKline, Pfizer, and Genetech (Roche). They have brought out money totaling over $350 million as of now. Also, he has been a leader in activities raising capital for Seattle Genetics. This gained more than $1.2 billion in financings both private and public. For example, this goes back to 2001 with an initial public offering found in the company.
Dr. Clay Siegall has a goal he wants to accomplish for in the world. The particular goal he has is to approach patients with cancer. To add to that, he wants to do better than what has been done with drugs that are targeted. The Dr. chose the job after something that happened in his own life. The Doctor when he was nineteen started seeing his father battle cancer. Dr. Siegall’s father passed away when he was twenty-four. That made him aware on the lack of tools that oncologists would have available. He wanted to make these tools better. He went to “George Washington University” to get a doctorate in genetics. He has been doing that job for thirty years.
Now some general information about Dr. Clay Siegall’s. The Dr. is located in Seattle, Washington in the region of the Greater Seattle Area. This is located in the U.S West Coast. This was in the Western part of the United States. In 1998 he co-founded “Seattle Genetics”. He is the Chairman, Chief Executive Officer, and President. For his education he went to George Washington University and got a Ph.D in Genetics. Also, he attended the University of Maryland where he got a B.S in Zoology. Finally, he has fifteen patents and has written more than seventy publications.